For the Inventor, By the Inventor

Enter assignee name

Pasadena, CA, United States of America

Arrowhead Pharmaceuticals, Inc.

USPTO Granted Patents = 102

% Expired Patents = 3.9

EPO Patents = 22

Trademarks = 2

Forward Citations = 160

Loading Chart...

Loading Chart...

135 inventors (with patents filed for the assignee):

Tao Pei (34 out of 35 patents)

Zhen Li (29 out of 35 patents)

Darren H Wakefield (26 out of 58 patents)

4. David B Rozema (22 out of 83 patents)

5. David L Lewis (19 out of 44 patents)

6. Lauren Almeida (18 out of 20 patents)

7. Rui Zhu (17 out of 20 patents)

8. Anthony Nicholas (17 out of 19 patents)

9. Jeffrey Carlson (15 out of 21 patents)

10. Steven B Kanner (14 out of 40 patents)

11. Stuart Milstein (12 out of 94 patents)

12. Christine I Wooddell (12 out of 15 patents)

13. Jon E Chatterton (12 out of 47 patents)

14. So Wong (11 out of 19 patents)

15. Aaron Almeida (10 out of 10 patents)

Core Competencies:

RNAi Agents

Hepatitis B Virus

Apolipoprotein C-III

Alpha-1 Antitrypsin

Gene Expression Inhibition

Therapeutic Compounds

Targeting Ligands

Compositions

Microtubule Associated Protein Tau

Integrin Ligands

Nucleotides

Organic Compositions

102 patents: Sort by Forward Citations

1. 12729377 - RNAi Agents And Compositions for Inhibiting Expression of Angiopoietin-Like 3 (ANGPTL3), And Methods Of Use (2026-09-08),

2. 12667619 - INTEGRIN TARGETING LIGANDS AND USES THEREOF (2026-06-30),

3. 12655428 - RNAi Agents for Inhibiting Expression of Beta-ENaC, Compositions Thereof, and Methods of Use (2026-06-16),

4. 12630826 - RNAi agents for inhibiting expression of xanthine dehydrogenase (XDH), pharmaceutical compositions thereof, and methods of use (2026-05-19),

5. 12551569 - RNAi agents for inhibiting expression of microtubule associated protein tau (MAPT), compositions thereof, and methods of use (2026-02-17),

6. 12527877 - ANTI-TRANSFERRIN RECEPTOR ANTIBODIES, CONJUGATES THEREOF, AND USES THEREOF (2026-01-20),

7. 12503696 - RNAi agents for inhibiting expression of inhibin subunit beta E (INHBE), pharmaceutical compositions thereof, and methods of use (2025-12-23),

8. 12442002 - RNAi agents for inhibiting expression of activin receptor-like kinase 7 (ALK7), compositions thereof, and methods of use (2025-10-14),

9. 12441756 - 5'-cyclo-phosphonate modified nucleotides (2025-10-14),

10. 12378558 - RNAi agents for inhibiting expression of complement factor B (CFB), pharmaceutical compositions thereof, and methods of use (2025-08-05),

11. 12365899 - RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3) (2025-07-22),

12. 12365897 - RNAi agents for inhibiting expression of mucin 5AC (MUC5AC), compositions thereof, and methods of use (2025-07-22),

13. 12221610 - RNAi agents for inhibiting expression of HIF-2 alpha (), compositions thereof, and methods of use (2025-02-11),

14. 12188017 - Compositions and methods for inhibiting gene expression of alpha-1 antitrypsin (2025-01-07),

15. 12173086 - Alpha-v beta-6 integrin ligands and uses thereof (2024-12-24),

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company primarily focused on the development and commercialization of RNA interference (RNAi) therapeutics. They utilize their proprietary Targeted RNAi Molecule (TRiM™) platform to design and develop RNAi-based drugs to treat various diseases. With a strong pipeline of innovative candidates, Arrowhead aims to address unmet medical needs and improve patient outcomes.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

Arrowhead Pharmaceuticals, Inc.

102 Patents

#4 in Pasadena, CA

#849 in California

#3,714 in US

#7,635 in the World

Pasadena, CA, United States of America

Arrowhead Pharmaceuticals, Inc.

Forward Citations = 160

135 inventors:

Tao Pei (34 out of 35 patents)

Zhen Li (29 out of 35 patents)

Darren H Wakefield (26 out of 58 patents)

4. David B Rozema (22 out of 83 patents)

5. David L Lewis (19 out of 44 patents)

Please report any incorrect information to [email protected]

Loading…